Dear Reader,

Dr. Mark Skousen here.

Elon Musk already made me about $800,000 richer.

Years ago, I got into a Tesla-heavy fund before anyone believed in him. Back when the "smart money" said electric cars were a joke. When the media was writing his obituary every other week.

I ignored them all. I trusted my research. I bet big.

That single bet turned into a near seven-figure position in under a decade.

Now I'm betting on Elon again — with SpaceX.

Bloomberg is calling the upcoming IPO "the biggest listing of ALL TIME." A $1.5 TRILLION valuation.

And after meeting Elon face-to-face at a private gathering of Wall Street elites, and throwing myself into my research, I'm convinced the announcement is coming soon.

March 26, 2026. That's my prediction.

I have an "access code" that lets you grab a pre-IPO stake before it happens.

I’d like to share it with you…

Elon already helped me make a small fortune. I believe he's about to do it again — for anyone smart enough to get in early.

Click here to see how to get your pre-IPO “access code”.

Yours for peace, prosperity, and liberty, AEIOU,

Dr. Mark Skousen
Macroeconomic Strategist, The Oxford Club

P.S. I've bet on Elon before and won. Now I'm doubling down. Just click on this link to see how to join me.

Hinge Health's AI Moat Might Be Its Patient Movement Data

By Leo Miller. Article Published: 2/23/2026.

Key Points

• PwC expects medical cost inflation to remain elevated, which strengthens the appeal of cost-reduction platforms like Hinge Health.
• Hinge’s MSK model is built to reduce therapy intensity and potentially avoid costly surgeries, supporting insurer adoption.
• Strong results are tempered by elevated stock-based compensation, though management expects SBC to normalize.
• Special Report: 48-Hour Alert: This Signal Just Flashed on (TICKER) (From Daily Edge Report)

The cost of healthcare in the United States is rising sharply. In its 2026 healthcare outlook, the Big Four accounting firm PricewaterhouseCoopers (PwC) emphasized this trend.

“The US healthcare system is heading into another year of powerful inflationary forces exerting pressure, with few deflationary forces in sight.” PwC estimates that group insurance medical costs rose 8.5% in 2024 — the fastest pace since 2012. It reports another 8.5% increase in 2025 and expects the same rate of growth in 2026.

Introducing "Elon Musk's Day-One Retirement Plan" (Ad)

Introducing "Elon Musk's Day-One Retirement Plan"

What if you could compress a lifetime of wealth-building…

Ten… twenty… even thirty years…

Into a single 24-hour window?

It sounds absurd.

But Elon Musk is about to make it a reality with something I'm calling…

"Day-One Retirement Plan." Click here to see the details.

In this environment, Hinge Health (NYSE: HNGE), a mid-cap healthcare stock, becomes an interesting option. Hinge's business model is built around reducing healthcare costs, and some of the industry's largest players are taking notice. Below we break down this fast-growing firm and assess its outlook after an impressive earnings report.

Understanding HNGE: Lowering Musculoskeletal Costs in Healthcare

Hinge Health focuses on a specific segment of care: musculoskeletal (MSK) physical therapy. Its virtual MSK platform delivers personalized therapy programs patients can perform at home via a mobile app, paired with wearable devices, AI coaching and human care teams.

Hinge reports that in 2024 its platform reduced the number of clinician hours required to support patients by roughly 95% versus traditional physical therapy programs. Lower clinician hours translate to lower costs, a primary reason employers and insurers adopt the platform.

For MSK conditions, the biggest cost driver is often surgery. Hinge contends its platform lowers the risk that patients will eventually require surgery by delivering consistent intervention and reducing barriers to adherence. Patients may find it easier to use Hinge's app at home than to schedule and travel to in-person appointments; increasing exercise adherence can reduce the likelihood of surgical intervention, saving insurers money.

One study that examined nearly 7,000 patients — half using Hinge and half receiving traditional care — found the incidence of spinal fusion surgery was 56% lower among Hinge users than in the comparison group.

Insurers are taking notice: Hinge now works with over 2,800 self-insured employers, including 45% of Fortune 500 companies. The company is also integrated with the U.S.'s five largest health plans, including UnitedHealth Group (NYSE: UNH), and with the three largest pharmacy benefit managers, making adoption easier for new customers.

Hinge Soars After Latest Earnings Report, But SBC Is Elevated

In the latest quarter, Hinge reported revenue of $171 million, a 46% increase year over year. Adjusted earnings per share rose 23% to $0.49. Both figures comfortably beat estimates, sending the shares up about 17%. For 2026 the company projects full-year revenue growth of 25% — a sharp deceleration from 2025's 51% growth — while forecasting an increase in adjusted operating margin from 20% to 21%. Free cash flow surged to $180 million in 2025, a roughly 300% increase versus 2024.

One major caveat: stock-based compensation (SBC). SBC is a non-cash way to compensate employees, but large SBC grants can materially affect reported cash metrics because, absent equity awards, the company would have paid more cash compensation. Hinge's SBC expense totaled $643 million, more than three times the free cash flow it generated, which distorts the headline cash-flow improvement.

On the positive side, Hinge expects SBC to be much smaller going forward, projecting averages of about $20 million to $25 million per quarter over the next four to eight quarters.

HNGE: An Intriguing AI Play on Healthcare

The MarketBeat consensus price target on Hinge Health sits near $57, implying roughly 35% upside. Analyst targets updated after the company's earnings fall slightly, averaging around $55, which still implies about 31% upside.

Hinge combines a compelling commercial model with a potential AI advantage. The company has amassed proprietary patient movement and engagement data from workouts and interactions with its AI assistant. That real-world motion data is valuable and not easily replicated, bolstering Hinge's defensibility as AI tools proliferate.

The stock trades at a forward price-to-earnings ratio near 21x, which is not stretched. There are several reasons to view Hinge as an attractive opportunity, but investors should be prepared for volatility: the company's market capitalization is under $4 billion, and sentiment toward software and high-growth health names can swing quickly.